Refining pathological evaluation of neoadjuvant therapy for adenocarcinoma of the esophagus

Figure 1 Kaplan-Meier curve of patients. A: Patients (n = 136) received neoadjuvant chemotherapy grouped by tumour regression grade. Left: Tumour Regression Grade (TRG) 1-5 (P < 0.0001); Right: TRG 1-2 vs TRG 3-5 (P < 0.0001); B: Patients (n = 136) received neoadjuvant chemotherapy grouped by presence or absence of lymph node downstaging (P < 0.0001); C: Patients (n = 113) with no pathological lymph node metastasis grouped by treatment (P = 0.042).

Figure 2 Percentage of patients who received neoadjuvant chemotherapy (n = 136) having lymph node downstaging grouped by Tumour Regression Grade. LN: Lymph node.

Figure 3 Kaplan-Meier curves of patients undergoing multimodal therapy (n = 136) grouped based on a combination of tumour regression grade and lymph node downstaging (P < 0. 0001). TRG: Tumour Regression Grade; LN: Lymph node.